11.08.07
Hospira
3Q Revenues: $838 million (+30%)
3Q Earnings: $59 million (+6%)
YTD Revenues: $2.5 billion (+26%)
YTD Earnings: $61 million (-68%)
Comments: Integration of Mayne Pharma helped drive revenue growth, while restructuring costs drove down earnings. Injectable Pharmaceutical Contract Manufacturing revenues were down 12% to $33.5 million in 3Q and down 20% to $111.6 million YTD.
3Q Revenues: $838 million (+30%)
3Q Earnings: $59 million (+6%)
YTD Revenues: $2.5 billion (+26%)
YTD Earnings: $61 million (-68%)
Comments: Integration of Mayne Pharma helped drive revenue growth, while restructuring costs drove down earnings. Injectable Pharmaceutical Contract Manufacturing revenues were down 12% to $33.5 million in 3Q and down 20% to $111.6 million YTD.